Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)

What the test measures

Type 1 diabetes (T1D) begins as a silent immune attack on the insulin-producing cells, and that attack leaves a fingerprint in the blood — autoantibodies — often years before any symptom. The standard panel measures four:¹ GADA (against glutamic acid decarboxylase), IA-2A (against insulinoma antigen-2), ZnT8A (against zinc transporter 8), and IAA (insulin autoantibodies).¹

The staging model

A 2015 scientific statement from JDRF, the Endocrine Society, and the American Diabetes Association turned these markers into a staging system that is now the global standard.² Stage 1 is two or more autoantibodies with normal glucose; stage 2 is two or more autoantibodies plus abnormal glucose — both presymptomatic; stage 3 is clinical, symptomatic diabetes.² This is why the panel matters: one antibody is uncertain, but two or more crosses a line.

Who to screen, and how predictive it is

In a pooled analysis of children followed from birth, those who developed multiple islet autoantibodies had a 69.7% risk of clinical diabetes within 10 years and roughly 84% within 15 years — versus only ~15% for a single antibody and ~0.4% for none.³ Risk accelerates closer to onset: among children with stage 2, the 2-year progression risk is about 48%.⁴ Critically, most future T1D is not in relatives — only about 1 in 10 people who develop T1D has a close family member with it — so screening only families misses the majority.⁵ General-population programs answer this: Germany's Fr1da study screened over 90,000 toddlers and found presymptomatic T1D in 0.31%.⁶

What early detection enables

The headline benefit is avoiding diabetic ketoacidosis (DKA) — the dangerous, sometimes fatal crisis that blindsides many families at diagnosis. Children found early and then monitored present far more gently: in one Fr1da analysis only 2.5% had DKA at clinical onset, with markedly lower HbA1c (6.8% vs 10.5%) and better-preserved insulin production than unscreened peers.⁷ Monitoring data from the TEDDY study show the same protective pattern.⁸ Early detection also opens the door to clinical trials and to teplizumab, the approved therapy that delays onset — for which stage 2 status (i.e., a positive autoantibody screen plus dysglycemia) is the entry requirement.⁹

Reach and cost

Screening is cheap relative to what it prevents. The U.S. ASK program reported a cost of about $4,700 per case detected, and Germany's Fr1da program roughly EUR 22 per child screened.¹⁰⁵ Programs are free to participants and increasingly open to all children regardless of family history (ASK covers all U.S. children and adults).¹¹

What's coming

Screening is moving from research toward routine care. The 2024 international consensus guidance now spells out how to monitor autoantibody-positive people in primary care, recommending confirmation on a second sample and structured follow-up.⁹ Expect home capillary / dried-blood-spot sampling to lower the burden further, integration of the panel into existing childhood blood draws, genetic-plus-antibody combined risk scores to sharpen targeting, and — as more delay therapies arrive — growing pressure to make population screening universal and reimbursed.⁹

References

1. Weiss A, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening (Fr1da). Diabetologia (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9630406/ ↩ ↩²

2. Insel RA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care (2015). https://doi.org/10.2337/dc15-1419 ↩ ↩²

3. Ziegler AG, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA (2013). https://doi.org/10.1001/jama.2013.6285 ↩

4. Weiss A, et al. Progression likelihood score identifies substages of presymptomatic type 1 diabetes (Fr1da). Diabetologia (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9630406/ ↩

5. Universal Screening for Type 1 Diabetes: About the Fr1da Study. Breakthrough T1D (accessed 2026). https://www.breakthrought1d.org/news-and-updates/universal-screening-type-1-diabetes-time-come/ ↩ ↩²

6. Ziegler AG, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA (2020). https://doi.org/10.1001/jama.2019.21565 ↩

7. Hummel S, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia (2023). https://doi.org/10.1007/s00125-023-05953-0 ↩

8. Jacobsen LM, et al. Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care (2022). https://doi.org/10.2337/dc21-0422 ↩

9. Phillip M, et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care (2024). https://doi.org/10.2337/dci24-0042 ↩ ↩² ↩³

10. McQueen RB, et al. Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. Diabetes Care (2020). https://doi.org/10.2337/dc19-2003 ↩

11. ASK (Autoimmunity Screening for Kids) Research Program. askhealth.org (accessed 2026). https://www.askhealth.org ↩